Drug Type Small molecule drug |
Synonyms MH048 |
Target |
Mechanism BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Malignant Neoplasm | Phase 2 | CN | 07 Dec 2021 | |
Non-Hodgkin Lymphoma | Phase 1 | CN | 07 Jan 2021 |
NCT04689308 (ASCO2022) Manual | Phase 1 | 12 | bdpgyqfkxy(ztmoibtngp) = Drug-related grade 3 TEAEs included platelet count decrease, neutrophil count decrease, lipase increase, and hypertension (one patient for each). mtslquhfvx (jvxvupuaqj ) View more | Positive | 02 Jun 2022 |